Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Evaluation of brain SPECT with 99mTc - TRODAT-1 in the differential diagnosis of Parkinsonism
Movement Disorders
P9 - Poster Session 9 (5:30 PM-6:30 PM)

The importance of this study can be expressed by the high incidence of Parkinsonism and the need for accurate and rapid diagnosis and the growing interest in non motor signs. The differential diagnosis of Parkinsonism mainly considers clinical findings, however, imaging tests and other markers may be essential tools for a quick diagnosis.

This study aimed to compare the results of the brain SPECT examination with the radiotracer 99mTc - TRODAT-1 (SPECT-TRODAT) in outpatients with Parkinsonism by correlating and comparing them with symptom severity and the presence of non-motor signs.

We evaluated 350 medical records of patients from a tertiary neurology service. We included patients examined by the same neurologist, and complete records, including detailed neurological examination and completed investigation scales. After a thorough review, 153 medical records were included. We used visual or qualitative evaluation; with normal or abnormal, symmetrical or asymmetrical results, with discrete, moderate, marked, and severe degrees of impairment. 

A direct relationship was found between severity in reduced SPECT-TRODAT in the group of patients with synucleinopathies (rho = 0.258, p = 0.005). Changes in SPECT-TRODAT had high correspondence with clinical changes (symmetry) in all types of parkinsonism. Regarding the correspondence of the exam with predominantly bilateral or unilateral impairment, there was a difference between patients with synucleinopathies (p= 0.041) and between this group and patients with secondary parkinsonism (p< 0.0001), which showed higher correspondences when the cases had a bilateral clinical presentation. The exam was instrumental in differentiating secondary parkinsonism from synucleinopathies. In the group of drug-induced parkinsonism, younger people were the ones who showed the greatest reductions in radiotracer binding. In this group, the presence of non-motor signs resulted in examinations with greater reductions in radiotracer binding. 

The authors concluded that the SPECT with 99mTc - TRODAT-1 was useful mainly in differentiating between synucleinopathies and secondary parkinsonism.
No disclosure on file
Giorgio Fabiani, MD (Dr. Giorgio Fabiani) Dr. Fabiani has nothing to disclose.
Carlos Henrique Ferreira Camargo, MD, MSc, PhD, FAAN (Inovare Serviços de Saude Ltda.) Dr. Camargo has nothing to disclose.
Rui Kleber Martins-Filho No disclosure on file
Gabriel Sampaio Froehner, MD Mr. Froehner has nothing to disclose.
Helio Afonso Ghizoni Teive, MD Dr. Teive has nothing to disclose.